Bedoelde u
a. dans

Zoekresultaten - 6 results

Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up.

to estimate the budgetary impact of reimbursement of direct-acting antivirals (DAA s). In Belgium, the restricted reimbursement criteria are mainly guided by regional seroprevalence estimates of 0.87% ...

Distribution of HCV genotypes in Belgium from 2008 to 2015.

possible impact of migration from endemic regions and prior to the increasing use of highly potent direct-acting antiviral (DAA) agents. Health Topics:  Hepatitis A, B, C, D en E Hepatitis A, B, C, D and ...

Establishment of a biological reference preparation for Hepatitis A Vaccine (Inactivated, Non-adsorbed)4425

Publication Type: Peer reviewed scientific article Authors: Stalder,A.; Costanzo,A.; Daas,G.; Rautmann,G.; Buchheit,K.H. Source: Pharmeur.Bio Sci.Notes, Volume 2010, Issue 1, Number 29, Straatsburg, ...

Establishment of the Ph. Eur. BRP for Varicella Vaccine Batch 1227

Publication Type: Peer reviewed scientific article Authors: Akkermans,A.; Geneviève Waeterloos; Kemiha,K.; Daas,A.; Milne,C. Source: Pharmeur.Bio Sci.Notes, Volume 2009-1, Number 54, p.45- 54 (2009) ...

Establishment of the Ph. Eur. BRP for varicella vaccine batch 1.

Publication Type: Peer reviewed scientific article Authors: A M Akkermans; Geneviève Waeterloos; K Kemiha; A Daas; C Milne Source: Pharmeur Bio Sci Notes, Volume 2009, Issue 1 (2009) Keywords: ...

QR code

QR code for this page URL